The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Optimizing immunotherapy in lung cancer: balancing intensification and de-escalation
Samreen Ahmed, FRCP, MD, MBBS, MSc, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the evolving role of immunotherapy in lung cancer treatment. She highlights the challenge of determining which patients may benefit from intensified treatments and which may need de-escalation, drawing parallels to breast cancer’s treatment evolution. Prof. Ahmed emphasizes the importance of biomarkers in predicting the need for treatment intensification and stresses the potential for optimizing therapy to minimize costs and improve patient quality of life. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
